V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryIn-Process Specs & Reconciliation (21 CFR 111.110)
Records · The complete guide

In-Process Specs & Reconciliation (21 CFR 111.110)

In short

A deep dive into 21 CFR 111.110, the regulatory requirement for establishing and verifying control points throughout the manufacturing process to ensure dietary supplement quality.

2,331 words · ~11 min read
A technician in protective clothing taking an in-process sample from a supplement blending vessel
In-process specifications under 21 CFR 111.110 set the control points checked while a supplement batch is being made, not just at the end.
On this page
  1. 01Understanding 21 CFR 111.110: The Foundation of In-Process Control
  2. 02Breaking Down the Regulatory Text: Requirements (a) through (e)
  3. 03Key In-Process Control Points in Supplement Manufacturing
  4. 04In-Process Specifications vs. Finished Product Specifications
  5. 05Roles and Responsibilities: The Quality Control Unit's Mandate
  6. 06When Specifications are Not Met: Material Review and Disposition
  7. 07Statistical Considerations for In-Process Monitoring
  8. 08Documentation: Connecting In-Process Data to the BPR
  9. 09Common Audit Findings and Compliance Gaps
  10. 10Modernizing In-Process Controls with Digital Systems
On this page · 10 sections
  1. 1Understanding 21 CFR 111.110: The Foundation of In-Process Control
  2. 2Breaking Down the Regulatory Text: Requirements (a) through (e)
  3. 3Key In-Process Control Points in Supplement Manufacturing
  4. 4In-Process Specifications vs. Finished Product Specifications
  5. 5Roles and Responsibilities: The Quality Control Unit's Mandate
  6. 6When Specifications are Not Met: Material Review and Disposition
  7. 7Statistical Considerations for In-Process Monitoring
  8. 8Documentation: Connecting In-Process Data to the BPR
  9. 9Common Audit Findings and Compliance Gaps
  10. 10Modernizing In-Process Controls with Digital Systems
AI · Explain it for MY operation

How does In-Process Specs & Reconciliation (21 CFR 111.110) apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01Understanding 21 CFR 111.110: The Foundation of In-Process Control

In the framework of dietary supplement manufacturing, quality is not a final destination reached only at the laboratory bench after a batch is finished. Instead, quality must be inherent to every step of the production cycle. This philosophy is codified in 21 CFR 111.110, a cornerstone of the FDA’s Current Good Manufacturing Practice (cGMP) regulations for dietary supplements. This specific regulation mandates that manufacturers establish and monitor in-process specifications at every critical point where control is necessary to ensure the final product meets its intended quality attributes.

The primary objective of 111.110 is to move away from 'inspection-based quality'—where failures are caught only after resources and materials have been fully expended—toward a proactive 'control-based quality' model. By identifying critical control points (CCPs) and setting rigorous specifications for them, manufacturers can detect deviations early, adjust processes in real-time, and prevent the creation of non-conforming batches. This regulation ensures that the dietary supplement is not only safe but also consistently manufactured according to the standards defined in the Master Manufacturing Record (MMR).

Compliance with 21 CFR 111.110 is not optional; it is a fundamental requirement for any firm involved in the manufacturing, packaging, or labeling of dietary supplements. Failure to establish these specifications is one of the most common citations in FDA Warning Letters, often leading to costly recalls and regulatory enforcement actions.

02Breaking Down the Regulatory Text: Requirements (a) through (e)

To understand the operational requirements of 21 CFR 111.110, one must look at its five distinct subsections. Each defines a specific duty that the manufacturer and their quality control (QC) unit must perform:

  • 111.110(a): Requires the establishment of in-process specifications for any point, step, or stage where control is necessary to ensure the quality of the supplement. This includes ensuring the product is packaged and labeled as specified in the MMR.
  • 111.110(b): Mandates the collection of representative samples of in-process materials. These samples must be sufficient for testing or examination to verify that specifications are being met.
  • 111.110(c): Compels the manufacturer to monitor these in-process points, steps, or stages. Monitoring can be manual (e.g., periodic weight checks by an operator) or automated (e.g., continuous temperature sensing).
  • 111.110(d): Requires the verification that in-process specifications are actually met. This is the act of comparing the monitoring data against the pre-defined limits.
  • 111.110(e): Assigns the ultimate responsibility to quality control personnel. They must review and approve the results of all in-process monitoring and testing to ensure the process remains in control.

The breadth of this regulation means that 'in-process' covers everything from the moment raw materials are weighed and staged until the final container is sealed and labeled. It creates a continuous chain of custody for quality, where each stage confirms the integrity of the work performed in the previous one.

03Key In-Process Control Points in Supplement Manufacturing

While the regulation does not list specific tests for every product type—recognizing the diversity of the supplement industry—common industry standards have emerged for different dosage forms. These control points are essential for maintaining process stability.

Powder Blending and Uniformity

Before a powder can be tableted or encapsulated, it must be uniform. In-process specifications for blending often include blend time, blender speed, and, most importantly, blend uniformity testing. If a blend is not uniform, individual tablets or capsules will have inconsistent potencies, potentially leading to sub-potent or dangerously over-potent products. Specifications usually involve testing multiple samples from different locations in the blender to ensure the Relative Standard Deviation (RSD) remains within a tight range, often ±10% or less of the target potency.

Tableting: Weight, Hardness, and Thickness

During compression, operators must perform frequent checks—often every 15 to 30 minutes. Key specifications include:

  • Individual Weight: Ensuring each tablet falls within a percentage of the target weight (e.g., ±5%).
  • Average Weight: Ensuring the mean weight of a sample group is correct, which directly correlates to the dosage of active ingredients.
  • Hardness (Breaking Force): If a tablet is too soft, it will crumble (friability); if it is too hard, it may not disintegrate or dissolve properly in the body.
  • Thickness: Variations in thickness can indicate issues with compression force or granulate flow, and can cause problems during the subsequent packaging stage.

Encapsulation: Fill Weights

For capsules, the primary in-process specification is the fill weight. Operators must regularly weigh empty shells and filled capsules to calculate the 'net fill weight.' Because capsule shells have their own weight variability, these checks must be performed meticulously to ensure that the active ingredient payload is accurate.

Liquids and Topicals: pH, Viscosity, and Specific Gravity

For non-solid dosage forms, in-process controls shift toward physical-chemical properties. pH is critical for stability and microbial resistance. Viscosity ensures the product pours or pumps correctly, and specific gravity (or density) is used to verify that ingredients were mixed in the correct proportions.

04In-Process Specifications vs. Finished Product Specifications

A common misunderstanding in supplement manufacturing is that in-process specs and finished product specs are redundant. In reality, they serve different, though complementary, purposes. Finished product specifications, governed by 21 CFR 111.70(e), are the final verification of the product's identity, purity, strength, and composition. In-process specifications, however, are focused on the *mechanics* of production.

For example, consider moisture content. An in-process specification might require a granulate to have a moisture level between 2% and 4% before it can be compressed. If the moisture is too high, the powder will stick to the tablet punches. By the time the product is a 'finished tablet,' the moisture might have equilibrated or been reduced by a coating process, and may no longer be a critical attribute for the final label claim. The in-process spec was there to protect the process, while the finished spec protects the consumer.

Furthermore, in-process specifications are often *tighter* than finished product specifications. If a final label claim allows for 90% to 110% of an active ingredient, the in-process blend uniformity might be set at 95% to 105%. This 'action limit' provides a buffer, ensuring that even with minor downstream variations, the final product will still comfortably meet its legal requirements.

05Roles and Responsibilities: The Quality Control Unit's Mandate

Under 21 CFR 111.110(e), the Quality Control Unit (QCU) is the ultimate arbiter of in-process quality. While production personnel are typically responsible for performing the tests and recording the data, the QCU must remain independent and provide oversight.

The QCU’s responsibilities include:

  • Establishing the Specifications: QC must approve the limits set in the Master Manufacturing Record. These limits must be based on scientific data, historical performance, or recognized compendial standards (like the USP).
  • Reviewing BPR Data: During the batch review process, QC must verify that every in-process check was performed at the correct frequency and that every result fell within the approved range.
  • Handling Deviations: If an in-process result falls outside of the specification (Out of Specification or OOS), the QCU must stop the process and initiate a formal investigation before the batch can proceed.

A common compliance failure is allowing production to 'average out' failing results. For instance, if one tablet in a sample is extremely heavy, but the average of the group is within spec, the individual failure cannot be ignored. The QCU must ensure that individual specifications are respected according to the approved sampling plan.

06When Specifications are Not Met: Material Review and Disposition

When an in-process specification is not met, the manufacturer must follow the procedures outlined in 21 CFR 111.113. This involves a 'material review and disposition.' The first step is to quarantine the material and prevent further processing. One cannot simply continue manufacturing with the hope that the finished product test will pass.

The investigation must determine the root cause of the failure. Was it an equipment malfunction? A human error in weighing? Or a problem with the raw material itself? The QCU then decides the fate of the batch. Possible outcomes include:

  1. Rejection: The material is destroyed or returned to the supplier.
  2. Reprocessing: In some limited cases, and only if allowed by the MMR and approved by QC, the material may be reprocessed. For example, if a blend is non-uniform, it might be returned to the blender for additional time, provided that 'blend-time-validation' data supports that this will not degrade the ingredients.
  3. Diversion: The material might be used for a different purpose that does not require the failed specification, though this is rare in supplements.

Crucially, all these decisions must be documented in writing. The FDA expects a clear 'paper trail' (or digital trail) showing that the failure was recognized, investigated, and resolved in a way that protects the consumer.

07Statistical Considerations for In-Process Monitoring

Setting in-process specifications requires a balance between statistical rigor and practical reality. A specification that is too tight may lead to frequent 'false alarms' and unnecessary batch rejections, while one that is too loose will fail to detect real process shifts.

Modern manufacturers often use Statistical Process Control (SPC) to manage in-process data. Tools like X-bar and R charts allow quality teams to see not just whether a result is 'in spec,' but whether it is trending toward a limit. If tablet weights are slowly increasing over a four-hour run, SPC can alert the operator to adjust the machine before the specification is actually breached.

Sampling plans also play a vital role. 21 CFR 111.110(b) requires 'representative samples.' This means the samples must be taken in a way that accurately reflects the entire lot. Taking ten tablets from the very beginning of a 500,000-tablet run is not representative. A statistically sound plan might involve taking samples at the beginning, middle, and end, or at fixed intervals based on the square root of the total batch size plus one (√n + 1).

08Documentation: Connecting In-Process Data to the BPR

Data that is not recorded is data that, in the eyes of the FDA, does not exist. The results of every in-process check required by 111.110 must be recorded in the Batch Production Record (BPR), as mandated by 21 CFR 111.255 and 111.260.

The BPR entry for an in-process check should include:

  • The date and time the check was performed.
  • The specific step or stage of the process.
  • The actual results obtained (not just 'Pass/Fail').
  • The initials or signature of the person performing the check.
  • The initials or signature of the QC person who reviewed the results (contemporaneously or during batch release).

In many manual systems, these records are kept on paper logs that are later scanned into a system. This introduces significant risks of transcription errors, lost pages, or 'post-dating'—all of which are major red flags during a cGMP audit.

09Common Audit Findings and Compliance Gaps

When the FDA inspects a facility, 21 CFR 111.110 is a frequent area of focus. Common citations include:

  • Lack of Written Specifications: The manufacturer performs checks (like weighing) but has no written limit in the MMR to define what is acceptable.
  • Inadequate Sampling: The number of samples taken is too small to provide a statistical basis for quality assurance.
  • Failure to Monitor: The MMR requires a check every 30 minutes, but the BPR shows gaps of two or three hours.
  • Lack of QC Oversight: Production personnel are signing off on their own failing results without a material review by the Quality Control Unit.
  • Missing Records: The firm claims to perform in-process checks but has no documentation to prove it.

These findings often indicate a deeper 'culture of quality' issue, where the in-process checks are seen as a bureaucratic hurdle rather than a vital tool for manufacturing excellence.

10Modernizing In-Process Controls with Digital Systems

The complexity of managing dozens of in-process specifications across multiple product lines makes manual, paper-based systems increasingly obsolete. Modern Manufacturing Execution Systems (MES) and purpose-built software like V5 Ultimate provide a technological solution to the challenges of 111.110 compliance.

V5 Ultimate digitizes the Master Manufacturing Record and Batch Production Record, enforcing in-process specifications in real-time. The system can be configured to require a weight check every 500 units; if the operator fails to perform the check, the batch is effectively 'paused' in the digital record. If a result is entered that is outside the pre-set specification, V5 triggers an immediate notification to the Quality Control Unit and prevents the batch from moving to the next stage until a material review is documented.

Digital systems also eliminate the risk of transcription errors. By interfacing directly with scales, pH meters, and hardness testers, V5 captures data straight from the source. This ensures the integrity of the record and provides the 'contemporaneous' documentation that regulators demand. Furthermore, the built-in analytics allow quality managers to monitor trends across months of production, turning regulatory data into a strategic asset for process improvement.

Frequently asked questions

Q.Does 21 CFR 111.110 require testing every single tablet?+

No. The regulation requires 'representative samples.' A statistically sound sampling plan allows you to verify the quality of the entire lot by testing a smaller subset at various stages of production.

Q.Can I use 'in-house' standards for in-process specifications?+

Yes, provided they are scientifically valid and documented in your Master Manufacturing Record. While compendial standards (like USP) are preferred, you can establish your own limits if you have the data to justify that they ensure the quality of the finished product.

Q.Who is responsible if an in-process check fails but the finished product passes?+

The failure of an in-process check is still a deviation that must be investigated under 111.113. A passing finished product test does not 'cancel out' an in-process failure. The process was out of control at that point, and the Quality Control Unit must determine if the batch integrity was compromised.

Q.What is the difference between an 'action limit' and a 'specification limit'?+

A specification limit is the regulatory boundary defined in the MMR; exceeding it requires a formal material review. An action limit (or alert limit) is a tighter, internal threshold used by operators to adjust the process before it reaches the specification limit, preventing a formal deviation.

Primary sources

  • 21 CFR 111.110 - Duties for in-process points, steps, or stages
  • FDA Guidance for Industry: Dietary Supplement cGMP Small Entity Compliance Guide
  • 21 CFR 111.113 - Material review and disposition

Further reading

  • MMR 21 CFR 111.205 Elements
    Understand the mandatory components of a Master Manufacturing Record where in-process specs must be defined.
  • BPR 21 CFR 111.255 Elements
    Learn how in-process data must be captured within the Batch Production Record for each lot.
  • Blend Time Validation
    A technical look at how to scientifically justify in-process specifications for powder mixing.
Software that covers In-Process Specs & Reconciliation (21 CFR 111.110)
V5 Ultimate (Dietary Supplements)
V5 Ultimate runs Master Manufacturing Records and executed Batch Production Records under 21 CFR Part 111, with mandatory…
V5 Ultimate Dietary Supplements
Written for supplement contract manufacturers and brand owners tired of surviving FDA 483s on paper.
Talk to us about In-Process Specs & Reconciliation (21 CFR 111.110)

Want to see how In-Process Specs & Reconciliation (21 CFR 111.110) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Inside V5
  • → QMS — quality records next to the work they concern.
  • → Document control — one version in force, every change signed and explained.
Regulatory anchors
  • 21 CFR 111.110
Related terms
  • → MMR Elements per 21 CFR 111.205
  • → BPR Elements per 21 CFR 111.255

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC